GRAIL to Present at Canaccord Genuity 45th Annual Growth Conference
GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for Wednesday, August 13 at 8:30 a.m. ET in Boston.
Investors can access both live and replay webcasts through GRAIL's investor relations website at investors.grail.com. The webcast recording will remain available for a minimum of 30 days following the event.
GRAIL (Nasdaq: GRAL), un'azienda sanitaria specializzata nella diagnosi precoce del cancro, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity. La presentazione è prevista per mercoledì 13 agosto alle 8:30 ET a Boston.
Gli investitori potranno accedere alle trasmissioni in diretta e alle repliche tramite il sito web delle relazioni con gli investitori di GRAIL all'indirizzo investors.grail.com. La registrazione del webcast sarà disponibile per almeno 30 giorni dopo l'evento.
GRAIL (Nasdaq: GRAL), una empresa de salud centrada en la detección temprana del cáncer, ha anunciado su participación en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity. La presentación está programada para el miércoles 13 de agosto a las 8:30 a.m. ET en Boston.
Los inversores pueden acceder a las transmisiones en vivo y a las repeticiones a través del sitio web de relaciones con inversores de GRAIL en investors.grail.com. La grabación del webcast estará disponible por un mínimo de 30 días después del evento.
GRAIL (나스닥: GRAL)은 조기 암 진단에 중점을 둔 의료 회사로, Canaccord Genuity 제45회 연례 성장 컨퍼런스에 참여할 것이라고 발표했습니다. 발표는 8월 13일 수요일 오전 8시 30분(동부시간)에 보스턴에서 예정되어 있습니다.
투자자들은 GRAIL의 투자자 관계 웹사이트 investors.grail.com을 통해 생중계 및 다시보기 웹캐스트에 접속할 수 있습니다. 웹캐스트 녹화는 행사 후 최소 30일간 제공됩니다.
GRAIL (Nasdaq : GRAL), une entreprise de santé spécialisée dans la détection précoce du cancer, a annoncé sa participation à la 45e conférence annuelle sur la croissance de Canaccord Genuity. La présentation est prévue pour le mercredi 13 août à 8h30 ET à Boston.
Les investisseurs peuvent accéder aux webdiffusions en direct et en replay via le site des relations investisseurs de GRAIL à l'adresse investors.grail.com. L'enregistrement du webcast restera disponible pendant au moins 30 jours après l'événement.
GRAIL (Nasdaq: GRAL), ein Gesundheitsunternehmen mit Fokus auf die frühzeitige Krebsdiagnose, hat seine Teilnahme an der 45. jährlichen Wachstums-Konferenz von Canaccord Genuity angekündigt. Die Präsentation ist für Mittwoch, den 13. August um 8:30 Uhr ET in Boston geplant.
Investoren können sowohl Live- als auch Wiederholungs-Webcasts über die Investor-Relations-Website von GRAIL unter investors.grail.com abrufen. Die Aufzeichnung des Webcasts wird mindestens 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-canaccord-genuity-45th-annual-growth-conference-302517743.html
SOURCE GRAIL, Inc.
FAQ
When is GRAIL (GRAL) presenting at the Canaccord Genuity Growth Conference?
How can investors access GRAIL's Canaccord conference presentation?
How long will GRAIL's Canaccord conference presentation be available for replay?
What is GRAIL's (GRAL) main business focus?
